MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.99
-0.90
-8.26%
After Hours: 10.12 +0.13 +1.30% 18:50 05/24 EDT
OPEN
10.54
PREV CLOSE
10.89
HIGH
10.60
LOW
9.78
VOLUME
1.31M
TURNOVER
0
52 WEEK HIGH
73.03
52 WEEK LOW
9.71
MARKET CAP
685.72M
P/E (TTM)
-3.6584
1D
5D
1M
3M
1Y
5Y
Goldman Sachs Adjusts Editas Medicine's Price Target to $8 from $10, Keeps Sell Rating
MT Newswires · 17h ago
Editas Medicine's Return On Capital Employed Insights
Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.
Benzinga · 5d ago
Editas Medicine Presents Data On SLEEK Gene Editing Technology At American Society Of Gene And Cell Therapy Annual Meeting
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression   Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persistence in an
Benzinga · 6d ago
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persistence in an ovarian cancer mouse model CAMBRIDGE, Mass.,...
GlobeNewswire · 6d ago
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
Zacks · 05/13 14:30
Editas Medicine Gets FDA Orphan Drug Designation for Blood Disorder Candidate
MT Newswires · 05/13 04:46
Editas Medicine granted Orphan Drug Designation for beta thalassemia candidate
The U.S. FDA has granted Orphan Drug designation to Editas Medicine (NASDAQ:EDIT) for EDIT-301, its candidate for beta thalassemia. The company is planning to dose the first person in a phase
Seekingalpha · 05/12 21:57
Editas Medicine Reports Received FDA Orphan Drug Designation For EDIT-301 For Treatment Of Beta Thalassemia
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing
Benzinga · 05/12 20:30
More
No Data
Learn about the latest financial forecast of EDIT. Analyze the recent business situations of Editas Medicine Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.76%Strong Buy
29.41%Buy
41.18%Hold
17.65%Under-perform
0.00%Sell
Analyst Price Target
The average EDIT stock price target is 32.38 with a high estimate of 80.00 and a low estimate of 10.00.
High80.00
Average32.38
Low10.00
Current 9.99
EPS
Actual
Estimate
-0.66-0.50-0.33-0.17
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 369
Institutional Holdings: 51.97M
% Owned: 75.71%
Shares Outstanding: 68.64M
TypeInstitutionsShares
Increased
80
6.12M
New
27
1.01M
Decreased
65
9.08M
Sold Out
72
3.64M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.06%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Mullen
Chief Financial Officer/Executive Vice President
Michelle Robertson
Executive Vice President/Chief Scientific Officer
Mark Shearman
Executive Vice President
Bruce Eaton
Senior Vice President
Li Chi
Lead Director/Independent Director
Jessica Hopfield
Independent Director
Meeta Chatterjee
Independent Director
Bernadette Connaughton
Independent Director
Andrew Hirsch
Independent Director
Emma Reeve
Independent Director
David Scadden
Independent Director
Akshay Vaishnaw
No Data
No Data
About EDIT
Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene-editing medicines to treat a range of serious diseases. It operates through the developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene-editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body and ex vivo gene-edited cell medicines, in which cells are edited with its technology.

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.